rigosertib: Clinical Trials

2 trials of rigosertib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Completed 1, Terminated 1

Follow rigosertib: new trials by email Literature Review of rigosertib trials Research Report on rigosertib

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
rigosertib, Any approved or standard-of-care therapy, best supportive care (BSC) - Myelodysplastic Syndrome, MDS
Phase 3TerminatedTraws Pharma, Inc.3722015-12-022022-09-26
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
ON 01910.Na - Myelodysplastic Syndromes, MDS
Phase 3CompletedTraws Pharma, Inc.2992010-11-012020-06-30

Conditions studied

Anemia, Refractory, with Excess of Blasts (2)  ·  Myelodysplastic Syndromes (2)  ·  Leukemia, Myelomonocytic, Chronic (1)

Sponsors

Traws Pharma, Inc. (2)

Countries

Belgium (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Spain (2)  ·  United States (2)  ·  Australia (1)  ·  Austria (1)  ·  Canada (1)  ·  Croatia (1)  ·  Czechia (1)  ·  Estonia (1)  ·  Hungary (1)  ·  India (1)  ·  Ireland (1)

Top investigators

Steven M. Fruchtman, MD (2)

Results publications

PMID 26968357, PMID 27400247

NIH funding

2015 (1)